MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:39Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Catecholamines]]
			[[Category:Sympathomimetics]]
			[[Category:Vasopressors]]
			[[Category:Inotropes]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #247

2026-05-23T04:04:21Z

parser-claude batch MedTemplate pre-fill, Top 300 #247

New page

{{MedTemplate
| generic = Epinephrine (adrenaline)
| brand = EpiPen, EpiPen Jr, Auvi-Q, Adrenaclick, Symjepi; many generic
| structure =
| classes = [[:Category:Catecholamines|Catecholamine]], [[:Category:Sympathomimetics|Sympathomimetic]], [[:Category:Vasopressors|Vasopressor]], [[:Category:Inotropes|Inotrope]]
| uses = <vote slug="anaphylaxis-use">Anaphylaxis (first-line; IM auto-injector for outpatient use)</vote>, <vote slug="cardiac-arrest-use">Cardiac arrest (ACLS)</vote>, <vote slug="severe-bronchospasm-use">Severe bronchospasm</vote>, <vote slug="croup-severe-use">Severe croup (racemic nebulized)</vote>, <vote slug="hemostasis-local-use">Local hemostasis (vasoconstriction with local anesthetics)</vote>, <vote slug="anesthesia-prolongation-use">Anesthesia prolongation in regional/local blocks</vote>
| starting_dose = Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care
| preparations = Auto-injectors 0.15 mg (Jr/pediatric), 0.3 mg (adult); 1 mg/mL (1:1,000) ampules for IM/SC use; 0.1 mg/mL (1:10,000) for IV use; 2.25% racemic nebulizer
| fda_max = Indication-specific; ACLS no fixed cumulative ceiling
| pill_id =
| routes = IM, IV, SC (less common), nebulized, intracardiac (historical only), endotracheal (legacy ACLS, not preferred)
| onset = IM: 5-10 minutes; IV: seconds; nebulized: 5-10 minutes
| duration = 5-15 minutes
| halflife = ~2 minutes<ref name="epipen-label">FDA Prescribing Information, EpiPen (epinephrine), Mylan/Viatris, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019430s062lbl.pdf</ref>
| bioavailability = IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)<ref name="epipen-label" />
| pregnancy = Used in life-threatening obstetric anaphylaxis without hesitation; benefits clearly outweigh.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="epinephrine-mech-claim">Epinephrine is a non-selective α1, α2, β1, β2 adrenergic agonist; in anaphylaxis the integrated effects — α1-mediated vasoconstriction (raising BP, reducing mucosal edema), β1-mediated cardiac stimulation, β2-mediated bronchodilation, and inhibition of mast cell and basophil mediator release — make it the only first-line therapy that simultaneously addresses every system involved.</vote> The narrow safe-bolus window for IV use (sharp risk of arrhythmia, hypertensive emergency, intracerebral hemorrhage) is why anaphylaxis dosing is '''IM, not IV''', outside critical care<ref name="epipen-label" />.
}}

== References ==
<references />

Epinephrine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #247